4:00 - 5:15pm [CEST]
The HIV vaccine field continues to advance through major scientific and technological developments. Innovations in structure-based immunogen design, B-cell lineage strategies, vector engineering, polyfunctional antibody responses and immune-modulating platforms are opening new pathways for both preventive and therapeutic vaccines. At the same time, the opportunities and challenges are co-evolving: long-acting prevention options, such as lenacapavir, shifts in global funding mechanisms, and new interest in integrating vaccine and cure strategies are shaping how product developers assess future directions.
In this dynamic environment, industry, biotech innovators and scientific partners play an increasingly important role in translating scientific insights into viable vaccine candidates. Continued coordination across these groups helps ensure that emerging scientific advances are informed by practical development considerations, that promising platforms are positioned effectively, and that the field maintains alignment around strategic priorities.
This three-part webinar series, “HIV vaccine innovation: Industry perspectives & partnership opportunities”, brings together public scientific updates, focused discussions on therapeutic vaccine development, and perspectives from biotech and other relevant stakeholders. By convening scientific, industry and development perspectives, the series aims to deepen shared understanding across the HIV vaccine ecosystem and support informed decision making for HIV vaccine research and development efforts.
The third webinar in the series will explore how biotech innovators are advancing vector engineering, nucleotide/viral platforms, small-scale manufacturing and translational development, including clinical studies. Building on insights from the first two webinars, this session will also emphasize how advances in biotech platforms can encourage collaboration in the field.